Table 1 Characteristics of SSc patients and patients with VEDOSS
Characteristics | SSc patients (n = 211) | UCTD (n = 29) | All patients (n = 240) |
|---|---|---|---|
Female, % | 79 | 93 | 80 |
Age (years), mean (SD) | 60 (13) | 51 (14) | 59 (14) |
Caucasian race, % | 97 | 100 | 97 |
Duration since RP onset (years), mean (SD) | 14 (12) | 8 (10) | 13 (12) |
Duration since first non-RP (years), mean (SD) | 13 (11) | na | na |
Diffuse disease, % | 18 | na | na |
Autoantibodies, % | |||
 Anti-topoisomerase I (Scl-70) | 29 | 7 |  |
 Anti-centromere | 45 | 34 |  |
 Anti-RNA polymerase III | 8 | 3 |  |
Organ involvement,% | |||
 Esophageal symptoms | 48 | 31 | 45 |
 Pulmonary hypertension | 15 | 0 | 13 |
 Interstitial lung disease | 49 | 0 | 42 |
 Renal crisis | 2 | 0 | 2 |
Disease activity/severity | |||
 Digital ulcers, % | 12 | 0 | 10 |
 mRSS, median (IQR) | 4 (2–9) | 0 (0–0) | 3 (0–9) |
 EUSTAR SSc activity score, median (IQR) | 1 (0.5–2.0) | na | na |
 FVC (% predicted), mean (SD) | 98 (21) | 99 (15) | 98 (20) |
 DLCO/va (% of predicted), mean (SD) | 79 (16) | 94 (17) | 82 (17) |
 DLCO/sb (% of predicted), mean (SD) | 71 (19) | 96 (13) | 74 (20) |